Patent classifications
G01N2800/368
ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR
Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.
SYSTEM AND METHOD FOR ESTIMATION OF DELIVERY DATE OF PREGNANT SUBJECT USING MICROBIOME DATA
The need for an accurate, early, and precise estimation of expected delivery date (EDD) for the pregnant subject is vital. A system and method for predicting a day/date of delivery for a pregnant subject using one or more microbiome samples collected from the pregnant subject is provided. The disclosure relates to applying machine learning techniques on the microbiome characterization data corresponding to the biological sample(s) collected from the pregnant subject. The method further comprises using the predicted EDD to suitably plan and take required medical treatment or precautions or medical advice for the pregnant subject to prevent any pregnancy and/or delivery related complications and to manage the delivery appropriately. The disclosure also provides compositions of the microbiome data which can potentially influence the delivery date, or the method provides exemplary compositions of the microbiome data which plays vital role in estimating the EDD of the pregnant subject.
NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECT AT RISK OF PRETERM DELIVERY
Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.
Method for Determining Risk of Pre-Term Birth
The present invention includes a method for determining pre-term birth or an associated clinical condition or an increased risk of pre-term birth or an associated clinical condition based on the presence and/or increased amount of specific amnion and/or chorion cells in a blood sample from a pregnant woman.
PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION
Embodiments are directed to methods of examining preimplantation factor (PIF) binding to a subject's circulating immune cells as a marker for immune dysregulation. Some embodiments are directed to methods of detecting a level of immune dysregulation sufficient to cause recurrent pregnancy loss (RPL), methods of detecting a level of immune dysfunction sufficient to cause endometriosis, and methods of detecting a level of immune dysfunction comprising administering an effective amount of PIF or an analog thereof, and examining its binding to circulating immune cells. Within those methods, an about twenty percent change in PIF binding to a subject's circulating immune cells indicates a level of immune dysfunction.
METHOD OF MAKING A POLYMERSOME
The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.
Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes
A method is taught for the accurate determination of the premature rupture of membranes (PROM), defined as spontaneous rupture of membranes before the onset of uterine contractions. More specifically, a lateral flow assay strip tests for at least two antigens to greatly limit or eliminate the possibility of false negatives. A built-in timer in the cassette holding the lateral flow assay further increases the accuracy of the test. A collection buffer vial with self-contained shipping and dropper caps and built-in stand is also taught.
Method of processing a biological sample
A method of processing of a biological sample containing multiple metabolites is described The method comprising the steps of pre-treating the biological sample with a metabolite extraction solvent to provide a pre-treated sample, separating a first aliquot of the pretreated sample by reverse phase liquid chromatography (RPLC) to provide a first eluent containing resolved hydrophobic metabolites, and separating a second aliquot of the pre-treated sample by hydrophilic interaction liquid interaction chromatography (HILIC) to provide a second eluent containing resolved hydrophilic metabolites. The first and second eluents are assayed using targeted tandem mass spectroscopy operated in multiple reaction monitoring mode. Each liquid chromatography step (LC) is directly hyphenated with the tandem mass spectrometry (MS/MS) into a single LC-MS/MS analysis. The extraction solvent typically comprises methanol, isopropanol and an acetate buffer.
ANALYTIC METHOD AND KIT FOR DIAGNOSING RECURRENT MISCARRIAGE
Provided are an analytical method for providing information necessary for diagnosing recurrent pregnancy loss, comprising measuring an expression level of HtrA4 protein or an expression level of a gene encoding the same in a subject’s sample, and a kit for diagnosing recurrent pregnancy loss, comprising a molecule capable of measuring an expression level of HtrA4 protein or an expression level of a gene encoding the same
Method for producing animal model of preterm birth and animal model of preterm birth produced by the method
The present invention relates to a method for producing an animal model of preterm birth and an animal model of preterm birth produced by the method. The animal model of the present invention can be effectively applied to investigate the causes and symptoms of preterm birth induced by cervical injury. The mortality rate of the animal model according to the present invention is low until preterm birth despite its induced preterm birth. In addition, the animal model of the present invention is produced in a higher yield than any other existing model. Furthermore, the preterm birth of the animal model according to the present invention is induced at a desired time point. Due to these advantages, the animal model of the present invention can be effectively applied to investigate the causes and mechanisms of preterm birth. The mortality rate of premature neonates born from the animal model of the present invention is considerably low and the premature neonates are immature. Therefore, the animal model of the present invention can be effectively applied to studies on complications of premature neonates.